Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Mathew, G ^a,d   Mitchell, A ^a,e   Down, J M ^b,f   Jacobs, L A ^a   Hamdy, F C ^b,g   Eaton, C ^b   Rosario, D J ^c   Cross, S S ^a   Winder, S J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Academic Unit of Urology   (United Kingdom)

^c Department of Oncology ^*  (United Kingdom)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF BRADFORD   (United Kingdom)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DYSTROGLYCAN; MYRISTIC ACID; PHOSPHOTYROSINE; TRANSCRIPTION FACTOR;

CELL NUCLEUS; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE; PROSTATE TUMOR; PROTEIN TRANSPORT; TUMOR CELL LINE; ARTICLE; DRUG EFFECT;

ANDROGENS; CELL LINE, TUMOR; CELL NUCLEUS; DYSTROGLYCANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MYRISTIC ACID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84885091062     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02792     Document Type: Article

References (54)

1. Henry, M. D. & Campbell, K. P. A role for dystroglycan in basement membrane assembly. Cell 95, 859-870 (1998). (Pubitemid 29014465)
2. Williamson, R. A. et al. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum. Mol. Genet. 6, 831-841 (1997). (Pubitemid 27239066)
3. Ervasti, J. M., Ohlendieck, K., Kahl, S. D., Gaver, M. G. & Campbell, K. P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345, 315-319 (1990).
4. Moore, C. & Winder, S. J. Dystroglycan versatility in cell adhesion: a tale of multiple motifs. Cell Com. Signal. 8, 3 (2010).
5. Durbeej, M.&Ekblom, P.Dystroglycan and laminins: glycoconjugates involved in branching epithelial morphogenesis. Exp. Lung Res. 23, 109-118 (1997). (Pubitemid 27131800)
6. Durbeej, M. et al. Non-muscle a-dystroglycan is involved in epithelial development. J. Cell Biol. 130, 79-91 (1995).
7. Moore, C. J. &Winder, S. J. The inside and out of dystroglycan post-translational modification. Neuromusc. Disord. 22, 959-965 (2012).
8. Cross, S. et al. The expression of b-dystroglycan is reduced or absent in the majority of human carcinomas. Histopathol. 53, 561-566 (2008).
9. Hara, Y. et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl. J. Med. 364, 939-946 (2011).
10. de Bernabe, D. B.-V. et al. Loss of a-dystroglycan laminin binding in epitheliumderived cancers Is caused by silencing of LARGE. J. Biol. Chem. 284, 11279-11284 (2009).
11. Bao, X. et al. Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc. Natl. Acad. Sci. USA 106, 12109-12114 (2009).
12. Akhavan, A. et al. Loss of cell-surface laminin anchoring promotes tumor growth and Is associated with poor clinical outcomes. Cancer Res. 72, 2578-2588 (2012).
13. Mitchell, A. et al. Dystroglycan function is a novel determinant of tumour growth and behavior in prostate cancer. Prostate 73, 398-408 (2013).
14. Oppizzi, M. L., Akhavan, A., Singh, M., Fata, J. E. & Muschler, J. L. Nuclear translocation of b-dystroglycan reveals a distinctive trafficking pattern of autoproteolyzed mucins. Traffic 9, 2063-2072 (2008).
15. Fuentes-Mera, L. et al. Characterization of a novel Dp71 dystrophin-associated protein complex (DAPC) present in the nucleus of HeLa cells: Members of the nuclear DAPC associate with the nuclear matrix. Exp. Cell Res. 312, 3023 (2006).
16. Mart́nez-Vieyra, I. A. et al. A role for b-dystroglycan in the organization and structure of the nucleus in myoblasts. Biochim. Biophys. Acta Mol. Cell Res. 1833, 698-711 (2013).
17. Singh, J. et al. Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res. 64, 6152-6159 (2004). (Pubitemid 39129416)
18. Miller, G. et al. Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse. Hum. Mol. Gen. 21, 4508-4520 (2012).
19. Thompson, O. et al. Modulation of cell spreading and cell-substrate adhesion dynamics by dystroglycan. J. Cell Sci. 123, 118-127 (2010).
20. Okamoto, I. et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J. Cell Biol. 155, 755-762 (2001). (Pubitemid 34286228)
21. Schroeter, E. H., Kisslinger, J. A. & Kopan, R. Notch-1 signalling requires ligandinduced proteolytic release of intracellular domain. Nature 393, 382-386, doi:10.1038/30756 (1998). (Pubitemid 28269713)
22. Sgambato, A. et al. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J. Cell. Physiol. 213, 528-539 (2007). (Pubitemid 47509736)
23. Batchelor, C. L. et al. Recruitment of Dbl by ezrin and dystroglycan drives membrane proximal Cdc42 activation and filopodia formation. Cell Cycle 6, 353-363 (2007).
24. Lara-Chacon, B. et al. Characterization of an Importin alpha/beta-recognized nuclear localization signal in beta-dystroglycan. J Cell Biochem 110, 706-717 (2010).
25. Mi, H., Muruganujan, A. & Thomas, P. D. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Research 41, D377-D386 (2013).
26. Glick, J. L., Meigs, T. E.,Miron, A. & Casey, P. J. RGSZ1, a Gz-selective Regulator of G Protein Signaling Whose Action Is Sensitive to the Phosphorylation State of Gz. J. Biol. Chem. 273, 26008-26013 (1998).
27. Wang, J. et al. RGSZ1, a Gz-selective RGS Protein in Brain: structure, membrane association, regulation by Gz phosphorylation, and relationship to a Gz GTPaseactivating protein subfamily. J. Biol. Chem. 273, 26014-26025 (1998).
28. Pellicoro, A. et al.Human and rat bile acid-CoA:amino acid N-acyltransferase are liver-specific peroxisomal enzymes: Implications for intracellular bile salt transport. Hepatol. 45, 340-348 (2007). (Pubitemid 46374590)
29. Cai, C. et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 21, 1835-1846, doi:me.2006-0480 (2007). (Pubitemid 47173795)
30. Sgambato, A. et al. Increased expression of dystroglycan inhibits the growth and tumorigenicity of human mammary epithelial cells. Cancer Biol. Ther. 3, 967-975 (2004). (Pubitemid 41351021)
31. Esser, A. K. et al. Loss of LARGE2 disrupts functional glycosylation of alphadystroglycan in prostate cancer. J. Biol. Chem. 288, 2132-2142 (2013).
32. Christiansen, J. J. & Rajasekaran, A. K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Research 66, 8319-8326 (2006). (Pubitemid 44449137)
33. Oppizzi, M. L., Akhavan, A., Singh, M., Fata, J. E. & Muschler, J. L. Nuclear translocation of beta-dystroglycan reveals a distinctive trafficking pattern of autoproteolyzed mucins. Traffic 9, 2063-2072 (2008).
34. Fuentes-Mera, L. et al. Characterization of a novel Dp71 dystrophin-associated protein complex (DAPC) present in the nucleus of HeLa cells: members of the nuclear DAPC associate with the nuclear matrix. Exp Cell Res 312, 3023-3035 (2006). (Pubitemid 44376478)
35. Seth, A. & Watson, D. K. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41, 2462-2478 (2005). (Pubitemid 41540623)
36. Gasi, D. & Trapman, J. Androgen regulation of ETS gene fusion transcripts in prostate cancer. Methods Mol Biol 776, 335-348 (2011).
37. Tomlins, S. A. et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56, 275-286 (2009).
38. Tomlins, S. A. et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
39. Veldscholte, J. et al. The androgen receptor in LNCaP cells contains amutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41, 665-669 (1992).
40. Petrovics, G. et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847-3852 (2005). (Pubitemid 40826884)
41. Attard, G. et al. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. J Clin Pathol 62, 373-376 (2009).
42. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
43. Ahlers, C. M. & Figg, W. D. ETS-TMPRSS2 fusion gene products in prostate cancer. Cancer Biol Ther 5, 254-255 (2006).
44. Spence, H. J., Dhillon, A. S., James, M. &Winder, S. J. Dystroglycan a scaffold for the ERK-MAP kinase cascade. EMBO Rep. 5, 484-489 (2004). (Pubitemid 38745039)
45. Casar, B., Pinto, A. & Crespo, P. ERK dimers and scaffold proteins: unexpected partners for a forgotten (cytoplasmic) task. Cell Cycle 8, 1007-10013 (2009).
46. Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599 (2007). (Pubitemid 47206938)
47. Hollenhorst, P. C. et al. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes & Development 25, 2147-2157 (2011).
48. Horoszewicz, J. S. et al. LNCaPModel ofHuman Prostatic Carcinoma. Cancer Res. 43, 1809-1818 (1983).
49. Lang, S. H., Stower, M. & Maitland, N. J. In vitro modelling of epithelial and stromal interactions in non-malignant and malignant prostates. Br J Cancer 82, 990-997 (2000). (Pubitemid 30085256)
50. Lang, S. H. et al. Differentiation of prostate epithelial cell cultures by matrigel/stromal cell glandular reconstruction. In Vitro Cell Dev Biol Anim 42, 273-280 (2006). (Pubitemid 44851885)
51. Gonzlez-RamÌrez, R., Morales-Lzaro, S. L., Tapia-RamÌrez, V., Mornet, D. & Cisneros, B. Nuclear and nuclear envelope localization of dystrophin Dp71 and dystrophin-associated proteins (DAPs) in the muscle cells: DAPs nuclear localization is modulated during myogenesis. J. Cell. Biochem. 105, 735-745 (2008).
52. James, M. et al. Adhesion-dependent tyrosine phosphorylation of b-dystroglycan regulates its interaction with utrophin. J. Cell Sci. 113, 1717-1726 (2000). (Pubitemid 30333121)
53. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863-14868 (1998). (Pubitemid 29003722)
54. King, J. Y. et al. Pathway analysis of coronary atherosclerosis. Physiol Genomics 23, 103-118 (2005).